Compare CCI & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCI | ILMN |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1B | 26.7B |
| IPO Year | 1998 | 2000 |
| Metric | CCI | ILMN |
|---|---|---|
| Price | $78.79 | $185.67 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 17 |
| Target Price | $104.69 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 4.2M | 1.9M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | 111.25 | ★ 170.87 |
| EPS | 0.34 | ★ 0.87 |
| Revenue | $4,264,000,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | N/A | $6.47 |
| Revenue Next Year | $1.72 | $5.58 |
| P/E Ratio | $232.88 | ★ $217.56 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $73.75 | $88.00 |
| 52 Week High | $115.76 | $196.66 |
| Indicator | CCI | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 57.35 |
| Support Level | $77.89 | $116.54 |
| Resistance Level | $92.92 | $196.66 |
| Average True Range (ATR) | 2.28 | 6.85 |
| MACD | 0.48 | -0.96 |
| Stochastic Oscillator | 55.91 | 50.14 |
Crown Castle owns or manages roughly 40,000 wireless towers in the United States. It leases space on its towers to wireless service providers, which install equipment to support their wireless networks. The company has a very concentrated customer base, with about 90% of its revenue from the Big Three US mobile carriers: Verizon, T-Mobile, and AT&T. Crown Castle has plans to divest its fiber business, which is expected to be finalized in the first half of 2026. After that, it will be a stand-alone tower operator. Crown Castle operates as a real estate investment trust.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.